Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis/Dermik’s Facial Repair Device Gets Compassionate Panel Nod

This article was originally published in The Gray Sheet

Executive Summary

FDA should actively restrict access to Aventis/Dermik Labs' Sculptra injectable facial restoration agent to patients with HIV-related lipoatrophy, according to FDA's General & Plastic Surgery Devices Panel
Advertisement

Related Content

Aventis HIV Dermal Filler Approval Precedes Broader Cosmetic Trial
Aventis HIV Dermal Filler Approval Precedes Broader Cosmetic Trial
Aventis Gains Expedited Review, March Panel For HIV-Indicated Dermal Filler
Aventis Gains Expedited Review, March Panel For HIV-Indicated Dermal Filler
Advertisement
UsernamePublicRestriction

Register

MT019962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel